ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO847

Persistent Hyperparathyroidism Post Kidney Transplantation

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Arabi, Ziad, Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
  • Althani, Abdullah Saleh, Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
  • Aljabri, Jawaher Nayyaf, Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
  • Tawhari, Mohammed Hadi, Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
  • Alflaiw, Ahmad I., Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Background

Hyperparathyroidism (HPT) is a frequent complication in chronic kidney disease and may persist in 20 to 50% of cases one year after kidney transplantation; and may contribute to long term allograft dysfunction and increased risk of fractures.
There is scant data on the prevalence of post-transplant HPT in kidney transplant patients in Saudi Arabia. The aim of this study is to evaluate the prevalence of this complication and to identify its risk factors in single center in Saudi Arabia.

Methods

In a retrospective study, data of 287 kidney transplant recipients, who underwent kidney transplant between January 2017 and May 2020 were collected. Data included demographic characteristic, history of hypertension, diabetes mellitus, coronary artery disease, duration of chronic kidney disease and dialysis therapy, dialysis modality, and type of vascular access. Serum iPTH measured prior to transplant then every 6 months post-transplant for 2 years.

Results

Of 287 kidney transplant recipients: 119 (41.5%) were diabetic and 38 (13.2%) had coronary artery disease. 231 (80.5%) had received living-donor kidneys and 56 (19.5%) were cadaveric recipients. iPTH was before transplant: 82.2±84.2 pmol/L, 1- 6 months: 27.5±31.4, 6-12 months: 28.8±35.9, and 12-24 months: 30.1±43.3. p value <0.001. Figure.1
Persistent hyperparathyroidism was found in 47 (16%) of patients at one year post renal transplant. The presence of diabetes mellitus as well as the duration of dialysis were predicators of persistent HPT. Type of transplant and allograft function did not seem to have any correlation.

Conclusion

In a single center experience, (16%) of kidney transplant patients had persistent HPT and the presence of diabetes mellitus and the duration of dialysis were important risk factors in its development.

iPTH post kidney transplatation